Communiqués Aptose Biosciences Inc.

Actions

APS

CA03835T3091

Marché Fermé - Toronto S.E. Autres places de cotation 21:59:59 15/07/2024			Varia. 5j.	Varia. 1 janv.
0,97 ^CAD	+3,19 %		-5,83 %	-71,04 %

18/06	Transcript : Aptose Biosciences Inc. - Shareholder/Analyst Call
14/06	Aptose Biosciences Inc. présente les résultats cliniques et précliniques du Tuspetinib au congrès hybride 2024 de l'Association européenne d'hématologie	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Aptose Announces Results from Annual and Special Meeting of Shareholders	18/06	AQ
Aptose Biosciences : 2024 EHA Poster – Safety and Efficacy of Tuspetinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)	14/06	PU
Aptose Biosciences : 2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax	14/06	PU
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress	14/06	AQ
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	31/05	AQ
APTE BIOS : Earnings Presentation	15/05	PU
APTE BIOS : Aptose 1Q Earnings Presentation	14/05	PU
Aptose Biosciences: Q1 Earnings Snapshot	14/05	AQ
Aptose Reports Results for the First Quarter 2024	14/05	AQ
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024	06/05	AQ
APTE BIOS : Aptose Corporate Presentation May 2024	03/05	PU
APTE BIOS : Material Agreement - Form 8-K	26/04	PU
APTE BIOS : Aptose Corporate Presentation April 2024	24/04	PU
Aptose Reports Results for the Fourth Quarter and Full Year 2023	26/03	AQ
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024	18/03	AQ
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option	31/01	AQ
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical	26/01	AQ
APTE BIOS : Aptose Corporate Presentation December 2023	26/12	PU
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting	10/12	AQ
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role	30/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Aptose Biosciences Inc.

Actions

APS

CA03835T3091

Communiqués

Filtres